Saturday, August 22, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Platforms Rush to Establish Content-Authenticity Standards Amid Leadership Shakeups and Sustained Capex
Within days of each other in mid-August 2026, Google, Anthropic, and Spotify moved to formalize AI content watermarking and labeling policies, signaling an industry-wide push toward self-governed provenance standards as generative AI output floods consumer platforms. The shift coincides with executive turnover at OpenAI (Brad Lightcap's departure) and Meta's public AI manifesto, all set against continued heavy AI infrastructure capital expenditure and finance-sector moves (e.g., Wall Street paying for algorithmic edges on social signals) that underscore AI's deepening entanglement with capital markets.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
JPMorgan Chase & Co.
Both facts report JPMorgan Chase & Co.'s revenue for the same fiscal period (FY 2025) with the same observation date (2025-12-31), but with different values: $182.447 billion vs. $185 billion. The ~1.4% difference ($2.553 billion) is too large to be explained by rounding alone and represents conflicting data for the identical time period.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,977
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,977 facts checked against source5,242 source documents archived
Work with this data → vianewsagency.com
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight

View original at finance.yahoo.com
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight The chronic rhinosinusitis with nasal polyps market growth is being driven by rising disease prevalence, greater awareness, and improved diagnostic ra…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The dynamics of the CRSwNP market are expected to change in the coming years due to the launch of emerging therapies such as Depemokimab, Verekitug (UPB-101), Lunsekimig, LY3650150, and others

    80% confidence

  • Treatment strategies are shifting beyond conventional intranasal corticosteroids, systemic steroids, and surgery toward targeted biologic therapies, enabling more personalized and sustained disease control for patients

    80% confidence

  • The US had around 2 million diagnosed prevalent cases of CRSwNP in 2025

    80% confidence

  • The 7MM accounted for 4.5 million diagnosed prevalent cases of CRSwNP in 2025, which are expected to increase during the study period

    80% confidence

  • Gender distribution of CRSwNP in the US shows male predominance with 55% of diagnosed prevalent cases being males

    80% confidence

  • The total chronic rhinosinusitis with nasal polyps treatment market size is expected to grow positively by 2036 in the leading markets

    80% confidence

  • GSK has expressed continued confidence in depemokimab's potential for CRSwNP and is maintaining discussions with the FDA

    80% confidence

  • CRSwNP is expected to see a rising disease burden over the forecast period (2026-2036), driven primarily by increasing prevalence, improved diagnosis, and evolving treatment approaches

    80% confidence

  • The United States accounted for the largest CRSwNP treatment market size in 2025, compared to other major markets

    80% confidence
Chronic Rhinosinusitis with Nasal Polyps Market Shows Strong Upward Momentum During the Forecast Period (2026-2036) as Demand for Advanced Therapies Rises | DelveInsight — Source | Via News | ViaNews Market